a2a receptor

ST3932 is a ST1535 metabolite, is a adenosine A2A receptor antagonist(Kis of 8 nM and 33 nM for A2A and A1 receptors, respectively).

KF21213 shows a high affinity for the adenosine A2A receptors (Ki=3.0 nM). KF21213 is a highly selective ligand for mapping CNS adenosine A2A receptors.

MRS 1523 can exert an antihyperalgesic effect through N-type Ca channel block and action potential inhibition in isolated rat dorsal root ganglion (DRG) neurons. MRS 1523 is an effective and selective adenosine A3 receptor antagonist Ki: 18.9 nM and 113 n

A2A receptor antagonist 1 (CPI-444 analog)是腺苷 A2A 和 A1受体的拮抗剂，Ki 值分别为4和264 nM。

A2A receptor antagonist 3 (Example 92) 是一种 adenosine A2a receptor 拮抗剂 (Ki: 0.4 nM)。A2A receptor antagonist 3 也可以结合 A2b 受体 (Ki: 37 nM)、A1 受体 (Ki: 107 nM) 和 A3 受体 (Ki: 1467 nM)。

A2A receptor antagonist 2 是高度选择性的 adenosine A2Areceptor 的有效拮抗剂 (IC50: 8.3 nM)。

GS-6201 (CVT-6883) 是选择性腺苷 A2B 受体拮抗剂。它对人腺苷 A2B 受体具有高亲和力和选择性 (Ki=22 nM)。它降低了小鼠急性心肌梗死后心脏中 caspase-1 的活性，并减弱了心脏重塑。它减弱了致敏小鼠 NECA，AMP 或变应原诱导的气道反应性。

XU1（Benzo[c][1,8]naphthyridin-6(5h)-One） 是一种 Aurora 蛋白激酶抑制剂，用于治疗适合激酶信号转导抑制、调节或调节的疾病。

Istradefylline (KW-6002) 是选择性的可口服的腺苷 A2A 受体拮抗剂，可用于研究药物滥用、睡眠障碍、肝损伤、帕金森病和不安腿综合征等的治疗和基础科学的试验。

ANR94 是一种有效的、选择性的腺苷 A2A 受体 (AA2AR) 拮抗剂，对 hAA2AR 的Ki 值为 46 nM。ANR94 具有用于帕金森病的研究潜力。

MRS-1706 是一种选择性A2B 腺苷受体的反向激动剂，对人 A2B、A2A、A1和 A3受体的Ki 值分别为 1.39、112、157 和 230 nM。

Ogerin 是选择性 GPR68正向别构调节剂(pEC50:6.83)。它能够抑制小鼠对恐惧记忆的回忆。它对 A2A 受体具有适中的拮抗作用(Ki:220 nM)。对 5-HT2B 受体的拮抗作用较弱(Ki:736 nM)。

A2A and A2B adenosine receptor partial agonist

SCH442416 (SCH 442416) 是选择性和可透过血脑屏障的腺苷A2A 受体拮抗剂，对人和大鼠 A2AR 的Ki 值分别为 0.048 和 0.5 nM，可用于在大鼠和灵长类动物大脑中对腺苷 A2A 受体成像。

Regadenoson (CVT-3146) 是一种腺苷衍生物和选择性 A2A 腺苷受体激动剂，具有冠状动脉舒张活性，对大鼠和猪腺苷 A2A 受体的Ki 分别为 290 和 1120 nM。它是血管扩张剂，可增加啮齿动物血脑屏障的通透性。

FR-194921 is a potent, selective, and orally active antagonist for central adenosine A1 receptors with cognitive-enhancing and anxiolytic activity. FR194921 has same binding affinity profile among human, rat, and mouse.

MRS3558 is an agonist of A3 adenosine receptors.

The A1, A2A, A2B, and A3 adenosine receptors (ARs) are ubiquitous G protein-coupled receptors. The four AR subtypes have been implicated in several areas of therapeutic interest such as stroke and other ischemic conditions, as well as inflammation, neurodegenerative diseases, diabetes, and sleep regulation. A3 AR antagonists are of interest as therapeutic agents in glaucoma agents and inflammation. CAY10498 is a potent and selective A3 AR antagonist exhibiting a Ki of 37 nM with 60 and 200-fold selectivity over A1 and A2A adenosine receptors, respectively. CAY10498 is also a structural analog of reversine, a dedifferentiation agent of embryonic progenitor cells. However, no dedifferentiation effects or any connection between A3 AR antagonism and dedifferentiation have been demonstrated.

Adenosine receptor antagonist 1 is a highly selective antagonist for the A2aR adenosine receptor, exhibiting an IC50 value of 0.29 nM. It demonstrates a remarkable 14-fold selectivity towards the A2aR receptor in comparison to the A2bR receptor.

AZD4635 (HTL1071) 是一种选择性的，具有口服活性的腺苷 A2A 受体 (A2AR) 拮抗剂。它结合人A2AR 的Ki 为 1.7 nM，对A2AR 的选择性是其他腺苷受体的 30 倍以上。

A1AR antagonist 6 (化合物 15) 是 A1 腺苷受体(A1AR)的有效的选择性拮抗剂，其pKi 值为 7.13，pIC50值为 6.38。

A1AR antagonist 5 (化合物 20) 是A1 腺苷受体(A1AR)的有效选择性拮抗剂，其pKi 值为 6.11，pIC50值为 5.83。

A1AR antagonist 4 (compound 22) is a highly developed chemical compound that acts as a potent and selective antagonist of the A1 adenosine receptor (A1AR). It possesses a pIC50 value of 5.51 and a pKi value of 6.29 [1].

Adenosine receptor inhibitor 1 is a highly potent and selective antagonist of adenosine receptor (AR). It exhibits exceptional affinity for A1 AR, A2A AR, A2B AR, and A3 AR, with respective Ki values of >1000, 68.5, >1000, >1000 nM. This compound demonstrates notable antinociceptive, anti-inflammatory, and peripheral analgesic properties. Therefore, Adenosine receptor inhibitor 1 holds great promise for investigating cancer and neurodegenerative diseases [1].